Stage IV ovarian epithelial cancer is the most advanced form of this disease, where cancer cells have spread beyond the ovaries to distant organs like the liver or lungs. Treatment focuses on controlling the disease, extending survival, and helping patients maintain the best possible quality of life, using a combination of surgery and medication therapies tailored to each person’s unique situation.

Understanding Treatment Goals in Advanced Ovarian Cancer

When ovarian epithelial cancer reaches stage IV, treatment becomes more complex, but options remain available. At this stage, cancer has traveled beyond the reproductive organs to distant parts of the body. In stage 4a, cancer cells have caused fluid buildup around the lungs, called pleural effusion, which is fluid accumulating in the space around the lungs. In stage 4b, the disease has reached the inside of the liver or spleen, lymph nodes outside the abdomen, or other organs such as the lungs.^[1]

The primary aim of treating stage IV ovarian epithelial cancer is to control the disease for as long as possible, helping patients live longer and feel better. Even when cure is not the goal, treatment can significantly improve symptoms and quality of life. Doctors design treatment plans based on several factors including where exactly the cancer has spread, whether a surgeon believes all visible cancer can be removed, and the patient’s overall health and ability to tolerate aggressive treatment.^[1][6]

Stage IV ovarian epithelial cancer includes cancers originating not only in the ovaries but also in the fallopian tubes and peritoneum (the tissue lining the abdominal cavity). These cancers are grouped together because they share similar cellular origins and respond to similar treatments. The most common subtype is high-grade serous carcinoma, which tends to spread quickly once it reaches the ovaries.^[7][9]

Standard treatments approved by medical organizations exist, but researchers continue investigating new therapies through clinical trials. The presence of distant metastases does not necessarily mean patients should avoid aggressive treatment. Studies show that maximal surgical effort combined with effective chemotherapy can substantially improve outcomes, even in advanced disease.^[15]

Standard Treatment Approaches

Surgery for Stage IV Disease

Surgery remains a cornerstone of treatment for stage IV ovarian epithelial cancer, though the approach must be carefully planned. The main surgical goal is cytoreductive surgery, also called debulking surgery, which means removing as much visible cancer as possible. The specialist surgeon, called a gynaecological oncologist, typically removes both ovaries, both fallopian tubes, the uterus including the cervix, and checks where cancer has spread in the pelvis and lymph nodes.^[1]

During the operation, the surgeon examines all areas where cancer might have spread and attempts to remove all visible disease. This can sometimes require removing portions of other organs where cancer has settled, such as sections of the intestines, liver tissue, or bladder. The amount of cancer remaining after surgery—called residual disease—is one of the most important factors affecting how long patients survive. Studies consistently show that patients with no visible cancer remaining after surgery live significantly longer than those with remaining tumors.^[8][15]

Not all patients with stage IV disease are candidates for surgery immediately. If cancer has spread very widely or if the patient is not healthy enough to tolerate a major operation, surgery may not be the first step. The medical team evaluates each case individually to determine the best timing and approach.^[1][6]

Chemotherapy Regimens

Chemotherapy uses powerful drugs to kill cancer cells throughout the body. For stage IV ovarian epithelial cancer, chemotherapy plays a critical role and is almost always part of the treatment plan. The standard approach combines two types of drugs: a platinum compound such as carboplatin or cisplatin, and a taxane drug such as paclitaxel or docetaxel. The most commonly used combination is carboplatin with paclitaxel, given through an intravenous line directly into the veins.^[1][12]

The timing of chemotherapy relative to surgery varies depending on individual circumstances. Some patients receive chemotherapy after surgery to destroy any remaining cancer cells—this is called adjuvant chemotherapy. Others receive chemotherapy before surgery to shrink tumors, making them easier to remove—this is called neoadjuvant chemotherapy—followed by surgery and then more chemotherapy afterward. This approach with surgery between chemotherapy cycles is called interval cytoreductive surgery.^[1][10]

Another specialized approach involves delivering heated chemotherapy directly into the abdomen during surgery. This technique, called hyperthermic intraperitoneal chemotherapy or HIPEC, bathes the abdominal cavity with heated chemotherapy drugs during the operation. However, this approach is not used in all centers and requires careful patient selection.^[1][18]

The duration of chemotherapy varies but typically involves several cycles over months. Most patients receive treatment every three weeks for six cycles, though this can be adjusted based on how the cancer responds and how well the patient tolerates treatment.^[12]

Targeted Cancer Drugs

Beyond traditional chemotherapy, some patients may receive treatment with targeted cancer drugs, which work differently by focusing on specific characteristics of cancer cells. The targeted drug bevacizumab (brand name Avastin) is sometimes used in stage IV ovarian cancer. Bevacizumab targets a protein called VEGF that helps tumors grow new blood vessels. By blocking this protein, the drug can help starve tumors of their blood supply.^[1][6]

Targeted drugs might be given alongside chemotherapy, on their own, or after chemotherapy has finished. The decision depends on various factors including the specific characteristics of the cancer and how it responds to initial treatment. Another group of targeted drugs called PARP inhibitors may be used in certain situations, particularly for patients whose cancers have specific genetic changes in genes called BRCA1 or BRCA2.^[1]

Supportive and Palliative Care

When surgery is not possible because cancer has spread too widely or the patient cannot safely undergo a major operation, chemotherapy alone may be given to shrink the cancer and slow its growth. Additional treatments help relieve symptoms even when cure is not the goal. This is called palliative treatment, which focuses on improving comfort and quality of life.^[1]

For example, doctors can drain fluid that accumulates in the abdomen (called ascites) or around the lungs. Radiotherapy might be used to relieve pain in specific areas where cancer is causing discomfort. These supportive treatments are integrated into the overall care plan to help patients maintain the best possible quality of life.^[1][18]

Treatment Being Tested in Clinical Trials

Researchers continuously work to find better ways to treat stage IV ovarian epithelial cancer. Clinical trials test new drugs, new combinations of existing drugs, and innovative treatment approaches. Participating in a clinical trial may give patients access to promising new therapies before they become widely available, while also contributing to medical knowledge that will help future patients.

Understanding Clinical Trial Phases

Clinical trials progress through different phases, each with a specific purpose. Phase I trials test a new treatment in a small group of people for the first time to evaluate safety, determine safe dosage ranges, and identify side effects. Phase II trials involve more people and aim to determine whether the treatment works against the cancer and to further evaluate safety. Phase III trials compare the new treatment to standard treatments in large groups of people to confirm effectiveness, monitor side effects, and collect information that allows the treatment to be used safely.^[9]

Patients with stage IV ovarian epithelial cancer may be eligible for various clinical trials testing different approaches. The availability of trials varies by location, with studies conducted in the United States, Europe, Poland, and other countries worldwide. Eligibility depends on factors including the specific characteristics of the cancer, previous treatments received, and overall health status.

Innovative Molecular Therapies

Many clinical trials focus on targeted therapies that work by interfering with specific molecules involved in cancer growth and spread. These drugs are designed based on understanding the biological processes that allow cancer cells to survive and multiply. Unlike traditional chemotherapy that affects all rapidly dividing cells, these targeted approaches aim to be more precise.

Researchers are testing various types of targeted molecules including drugs that block specific growth factor receptors on cancer cells, drugs that interfere with signaling pathways inside cancer cells that tell them to grow and divide, and drugs that help the immune system recognize and attack cancer cells. Some of these treatments are being studied alone, while others are tested in combination with standard chemotherapy or other targeted drugs.

Immunotherapy Approaches

Immunotherapy represents an exciting area of cancer research that harnesses the body’s own immune system to fight cancer. Cancer cells often have ways of hiding from or suppressing the immune system. Immunotherapy drugs work by helping the immune system recognize cancer cells as foreign invaders that should be destroyed.

Several types of immunotherapy are being studied in ovarian cancer clinical trials. Checkpoint inhibitors are drugs that release brakes on the immune system, allowing immune cells to attack cancer more effectively. These drugs target proteins like PD-1, PD-L1, or CTLA-4 that normally prevent the immune system from attacking the body’s own cells, but which cancer cells exploit to avoid detection. By blocking these checkpoint proteins, the drugs help immune cells recognize and destroy cancer cells.

Another immunotherapy approach being studied involves cancer vaccines, which are designed to stimulate the immune system to attack specific proteins found on ovarian cancer cells. Unlike vaccines that prevent disease, cancer vaccines are treatment vaccines intended to boost the immune response against existing cancer. Clinical trials are testing various vaccine formulations and combinations with other treatments.

PARP Inhibitors in Clinical Development

PARP inhibitors are a class of targeted drugs that block an enzyme called PARP, which helps repair DNA damage in cells. Cancer cells with certain genetic mutations, particularly in BRCA1 or BRCA2 genes, rely heavily on PARP to repair DNA. When PARP is blocked, these cancer cells cannot repair their DNA and die. While some PARP inhibitors are already approved for certain situations, clinical trials continue testing new PARP inhibitors, new combinations, and expanded uses in different groups of patients.

Trials are investigating PARP inhibitors given after initial chemotherapy to help prevent cancer from growing back, in combination with other targeted drugs, and in patients whose cancers have genetic characteristics beyond just BRCA mutations that might make them vulnerable to PARP inhibition. These studies aim to identify which patients benefit most from this approach and how to use these drugs most effectively.

Combination Strategies

Many current clinical trials test combinations of different treatment approaches. For example, researchers are studying combinations of immunotherapy with targeted drugs, PARP inhibitors combined with anti-angiogenic drugs (drugs that prevent tumors from growing new blood vessels), and various targeted drugs combined with standard chemotherapy. The rationale is that attacking cancer through multiple mechanisms simultaneously may be more effective than single approaches.

These combination trials carefully evaluate not only whether the combinations work better than standard treatment, but also whether the side effects are manageable. Adding drugs together can sometimes increase side effects, so finding the right balance between effectiveness and tolerability is crucial.

Novel Drug Delivery Methods

Beyond new drugs themselves, researchers are exploring innovative ways to deliver treatments. Some clinical trials test improved methods of delivering chemotherapy directly into the abdominal cavity, refined versions of intraperitoneal chemotherapy that may be better tolerated than earlier approaches. Other studies investigate nanoparticle-based drug delivery systems that can carry chemotherapy drugs specifically to cancer cells while sparing normal tissues, potentially increasing effectiveness while reducing side effects.

Preliminary Results and Ongoing Research

While many trials are still ongoing without final results, some early-phase studies have reported encouraging preliminary findings. Certain immunotherapy combinations have shown promise in subgroups of patients whose tumors have specific characteristics. Some targeted therapy combinations have demonstrated improved progression-free survival in early studies, meaning patients went longer before their cancer grew or spread. Novel PARP inhibitor combinations have shown activity even in some patients whose cancers don’t have BRCA mutations.

However, it’s important to understand that preliminary results from early-phase trials need confirmation in larger Phase III studies before any new treatment becomes standard. The process of developing and approving new cancer treatments typically takes many years of careful research. Patients interested in clinical trials should discuss options with their healthcare team, who can explain available trials, eligibility requirements, potential benefits and risks, and help determine whether trial participation makes sense for their individual situation.^[9]

Most common treatment methods

• Surgery (Cytoreductive/Debulking Surgery)
  • Removal of both ovaries, fallopian tubes, uterus, and cervix by a specialist gynaecological oncologist
  • Removal of as much visible cancer as possible from the pelvis, abdomen, and other affected organs
  • May include removing sections of intestines, liver tissue, spleen, or other organs where cancer has spread
  • Complete removal of all visible disease (no residual disease) is associated with significantly better survival
  • Can be performed as primary surgery before chemotherapy or as interval surgery between chemotherapy cycles
• Chemotherapy
  • Standard combination of carboplatin (platinum drug) with paclitaxel (taxane drug) given intravenously
  • Alternative combinations include cisplatin with paclitaxel or docetaxel
  • Typically given every three weeks for six cycles, though duration may vary
  • Can be given after surgery (adjuvant chemotherapy) or before and after surgery (neoadjuvant chemotherapy with interval surgery)
  • Hyperthermic intraperitoneal chemotherapy (HIPEC) delivers heated chemotherapy directly into the abdomen during surgery
  • May be given alone when surgery is not possible to shrink cancer and slow growth
• Targeted Cancer Drugs
  • Bevacizumab (Avastin) targets blood vessel growth that feeds tumors
  • PARP inhibitors for cancers with BRCA1 or BRCA2 mutations or certain other genetic characteristics
  • Can be given with chemotherapy, alone, or after chemotherapy depending on the situation
  • Selection depends on specific cancer characteristics and genetic testing results
• Radiotherapy
  • Used primarily for symptom relief (palliative treatment) rather than cure
  • Helps relieve pain in specific areas where cancer is causing discomfort
  • May be used to treat isolated areas of disease
• Supportive and Palliative Treatments
  • Drainage of fluid accumulation in the abdomen (ascites) or around the lungs (pleural effusion)
  • Treatment for bowel obstruction caused by cancer
  • Pain management medications to improve comfort
  • Nutritional support and management of digestive symptoms
  • Aimed at improving quality of life and managing symptoms when cure is not the primary goal